- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Notice to convene Evaxion's Annual General Meeting | 315 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, announces that its... ► Artikel lesen | |
| Do | Notice to convene Evaxion's Annual General Meeting | 2 | GlobeNewswire (USA) | ||
| 17.03. | Evaxion presents cancer vaccine data at AACR meeting in April | 1 | Investing.com | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 17.03. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | Evaxion to present new data at AACR Annual Meeting | 516 | GlobeNewswire (Europe) | Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion's AI-Immunology platform... ► Artikel lesen | |
| 06.03. | Evaxion outlines expanded cash runway into 2H 2027 and anticipates data milestones for EVX-01 and EVX-04 | 2 | Seeking Alpha | ||
| 05.03. | Evaxion Biotech ADS GAAP EPS of -$0.02 beats by $0.01 | 4 | Seeking Alpha | ||
| 05.03. | Insights into Evaxion Q4 Earnings | 4 | Benzinga.com | ||
| 05.03. | Evaxion Earnings Report: Q4 Overview | 7 | Benzinga.com | ||
| 05.03. | Evaxion announces business update and full year 2025 financial results | 604 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business... ► Artikel lesen | |
| 05.03. | Evaxion A/S - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | ||
| 05.03. | Evaxion plans to file 2025 annual report later today | 302 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, will slightly delay... ► Artikel lesen | |
| 04.03. | Evaxion Biotech's Earnings: A Preview | 1 | Benzinga.com | ||
| 02.03. | Evaxion to announce business update and full year 2025 financial results on March 5, 2026 | 225 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, will provide a business... ► Artikel lesen | |
| 27.02. | Evaxion A/S vergibt über 9 Millionen Optionsscheine an Verwaltungsrat, Management und Mitarbeiter | 3 | Investing.com Deutsch | ||
| 27.02. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.02. | Maxim Group initiates Evaxion Biotech stock with buy on AI platform | 1 | Investing.com | ||
| 13.01. | Evaxion expands AI-Immunology platform into autoimmune diseases | 846 | GlobeNewswire (Europe) | Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focusIn future, Evaxion's proprietary AI-Immunology platform will enable the discovery and development of drug candidates... ► Artikel lesen | |
| 07.01. | Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week | 312 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will present at the Biotech... ► Artikel lesen | |
| 07.01. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 Weiter >>
78 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 75,00 | -2,72 % | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| EVOTEC | 4,172 | +0,53 % | Evotec: Misstrauen trotz Millionen | Eine Summe in Höhe von zehn Millionen Dollar (rund 9,2 Millionen Euro) überweist der amerikanische Pharmakonzern Bristol-Myers Squibb dem Hamburger Biotechunternehmen. Es handelt sich um eine Meilensteinzahlung... ► Artikel lesen | |
| QIAGEN | 34,130 | -0,34 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| PAION | 0,052 | -20,91 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| AMGEN | 299,85 | -0,43 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,374 | +0,20 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| STRYKER | 285,80 | -1,62 % | Stryker Corporation: Stryker announces Annual Meeting of Shareholders | ||
| BIOGEN | 158,45 | 0,00 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,800 | +2,00 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| OCUGEN | 1,710 | -1,55 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,800 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.